• "Fast but not so furious": A condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
• 3D osteocyte lacunar morphometry of human bone biopsies with high resolution microCT: From monoclonal gammopathy to newly diagnosed multiple myeloma
• A case of atypical IgA paraprotein interference on multiple chemistry assays: How to deal with it
• A Case Report of the Atypical Presentation of Multiple Myeloma Manifesting as a Sternal Mass
• A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
• A multicenter, prospective, phase, single-arm study on the treatment of newly diagnosed multiple myeloma with domestic bortezomib in combination with lenalidomide and dexamethasone
• A roadmap towards improving outcomes in multiple myeloma
• Advances and challenges in anti-cancer vaccines for multiple myeloma
• Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting
• An unbiased lncRNAs dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for Multiple Myeloma
• Analysis of a plerixafor sparing mobilization regimen for autologous hematopoietic cell transplant in multiple myeloma
• Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
• Atypical Central Retinal Vein Occlusion in an Older Man With Multiple Myeloma: A Case Report
• Bortezomib-encapsulated metal-phenolic nanoparticles for intracellular drug delivery
• Calcium-Based Imaging of the Spine at Dual-Layer CT and Evaluation of Vertebral Fractures in Multiple Myeloma
• Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study
• Case report: DKRd regimen in the treatment of newly diagnosed POEMS syndrome and literature review
• Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma
• Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma
• Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)
• ciRS-7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma
• Clinical significance of FLC tests in patients without other evidence of hematologic disorder
• Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison
• Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
• Correlation between initial alkaline phosphatase levels and overall survival in newly diagnosed multiple myeloma patients
• Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma
• Detecting M-Protein via Mass Spectrometry and Affinity Beads: Enrichment With Mixed Kappa-Lambda Beads Enables Prompt Application in Clinical Laboratories
• Development of a Novel Peptide-Based PET Tracer [(68)Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma
• Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib
• Disparities in time to treatment with oral antimyeloma medications
• Dramatically elevated plasma vascular endothelial growth factor levels from influenza A infection in polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome: A case report
• Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
• Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone
• Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd pl
• Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
• Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years
• Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting
• Enhancing mutation detection in multiple myeloma with an error-corrected ultra-sensitive NGS assay without plasma cell enrichment
• Epigallocatechin gallate induces apoptosis in multiple myeloma cells through endoplasmic reticulum stress induction and cytoskeletal disruption
• Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists
• Evolutionarily conserved enhancer-associated features within the <em>MYEOV</em> locus suggest a regulatory role for this non-coding DNA region in cancer
• Exercise-downregulated CD300E acted as a negative prognostic implication and tumor-promoted role in pan-cancer
• Expression and Function of FAM72A Gene in Multiple myelomaFAM72A
• FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population
• Features that characterize monoclonal light chain ("myeloma") cast nephropathy with immunofluorescence challenges and emphasis on electron microscopy
• Gamma gap as a prognostic marker of treatment response in patients with multiple myeloma
• Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)
• Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance
• How to Identify and Manage High-Risk Smoldering Multiple Myeloma
• Identification of clinical-biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation
• Immunoglobulin class-switch recombination: Mechanism, regulation, and related diseases
• Immunoglobulins: Mechanistic Approaches in Moderation of Various Inflammatory and Anti-Inflammatory Pathways
• Impact of CD34/CD309 expression in circulating endothelial progenitor cells on prognosis and response to bortezomib therapy in multiple myeloma
• Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents
• Incidence and prevention of skeletal-related events in multiple myeloma patients: A population-based real-world experience
• Incidence of and risk factors for venous thrombosis in hospitalized patients with hematologic malignancies: A single-center, prospective cohort study
• Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma
• Influence of structural racism on cancer health disparities: Tailoring measures relevant to multiple myeloma
• Information preferences of patients with chronic blood cancer: A qualitative investigation
• Kidney transplantation in multiple myeloma in 2023: A short review
• Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients
• Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon
• Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
• Monoclonal gammopathy of renal significance from the perspective of nephrologists
• Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy
• Multidimensional role of adapalene in regulating cell death in multiple myeloma
• Multiple brown tumor in late adolescence mimicking bone metastasis: A challenging case report
• Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity
• Multiple myeloma in Latin America: A systematic review
• Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics
• Multiple myeloma: unplanned diagnostic pathways and association with risk factors and survival - a nationwide register-based cohort study in Denmark
• Multisite distribution of fibrillary inclusions in a patient with light chain proximal tubulopathy: A case report
• Myeloma CAR T-cell therapy toxicity timing: What is the right amount of post-treatment monitoring for our patients?
• No Role for Tandem Autologous Stem Cell Transplantation in Modern Treatment Paradigms for Transplant Eligible Multiple Myeloma
• Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
• Parkinsonism Following Chimeric Antigen Receptor T Cell Therapy
• Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation
• Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration
• Possible mechanisms underlying the regulation of postmenopausal osteoporosis by follicle-stimulating hormone
• Prognosis and immune biomarkers of multiple myeloma
• Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
• Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers
• Role and timing of chromosome deletions in multiple myeloma
• Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system
• Size-Exclusion Chromatography: A Path to Higher Yield and Reproducibility Compared to Sucrose Cushion Ultracentrifugation for Extracellular Vesicle Isolation in Multiple Myeloma
• Solitary testicular plasmacytoma: a case report
• Somatic mutation phasing and haplotype extension using linked-reads in multiple myeloma
• Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma
• Steatotic liver disease in the context of hematological malignancies and anti-neoplastic chemotherapy
• Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma
• Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
• The Impact of Additive PICOs in a European Joint Clinical Health Technology Assessment
• The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
• The MYC-MAF-SAGA axis drives oncogenic gene expression in multiple myeloma
• The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy
• The SAGA acetyltransferase module is required for the maintenance of MAF and MYC oncogenic gene expression programs in multiple myeloma
• Trends in multiple myeloma incidence, prevalence, mortality, and survival rate in South Korea: a nationwide population-based study
• Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)
• Variation in immunoglobulin use and impact on survival in myeloma
• Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab